Pregled bibliografske jedinice broj: 1268393
Emerging Therapies for the Treatment of Atherosclerotic Cardiovascular Disease: From Bench to Bedside
Emerging Therapies for the Treatment of Atherosclerotic Cardiovascular Disease: From Bench to Bedside // International journal of molecular sciences, 24 (2023), 9; 8062, 17 doi:10.3390/ijms24098062 (međunarodna recenzija, pregledni rad, znanstveni)
CROSBI ID: 1268393 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Emerging Therapies for the Treatment of Atherosclerotic
Cardiovascular Disease: From Bench to Bedside
Autori
Kumrić, Marko ; Ulrić, Hrvoje ; Božić, Joško ; Vilović, Marino ; Tičinović Kurir, Tina ; Glavaš, Duška ; Mirić, Dino ; Zanchi, Jakša ; Bradarić Šlujo, Anteo ; Lozo, Mislav ; Borovac, Josip Anđelo
Izvornik
International journal of molecular sciences (1422-0067) 24
(2023), 9;
8062, 17
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pregledni rad, znanstveni
Ključne riječi
atherosclerosis ; cholesterol ; inflammation ; therapy ; statins ; bempedoic acid ; PCSK9 inhibitors ; inclisiran ; alirocumab ; omega-3 ; evolocumab ; siRNA ; outcomes ; coronary artery disease ; heart disease ; ischemic heart disease ; dysplipidemia ; hypolipemic therapies
Sažetak
Primarily a consequence of a sedentary lifestyle, atherosclerosis has already reached pandemic proportions, and with every year the burden of it is only increasing. As low-density lipoprotein cholesterol (LDL-C) represents a crucial factor in atherosclerosis formation and progression, stringent lipid-lowering therapy could conceivably be the key to preventing the unfavorable outcomes that arise as a consequence of atherosclerosis. The use of statins in lipid-lowering is often burdened by adverse events or is insufficient to prevent cardiovascular events as a monotherapy. Therefore, in the present review, the authors aimed to discuss the underlying mechanisms of dyslipidemia and associated atherosclerotic cardiovascular disease (ASCVD) and preclinical and clinical trials of novel therapeutic approaches to its treatment, some of which are still in the early stages of development. Apart from novel therapies, a novel change in perspective is needed. Specifically, the critical objective in the future management of ASCVD is to embrace emerging evidence in the field of atherosclerosis, because clinicians are often burdened by common practice and personal experience, both of which have been proven futile in the setting of atherosclerosis.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
KBC Split,
Medicinski fakultet, Split
Profili:
Mislav Lozo
(autor)
Marko Kumrić
(autor)
Josip Anđelo Borovac
(autor)
Tina Tičinović Kurir
(autor)
Jakša Zanchi
(autor)
Marino Vilović
(autor)
Dino Mirić
(autor)
Anteo Bradarić-Šlujo
(autor)
Duška Glavaš
(autor)
Joško Božić
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE